{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:43:52Z","timestamp":1793321032745,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.05.031","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T23:01:48Z","timestamp":1499209308000},"page":"6015-6023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Development of vaccines against Crimean-Congo haemorrhagic fever virus"],"prefix":"10.1016","volume":"35","author":[{"given":"Stuart D.","family":"Dowall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.05.031_b0005","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.ijantimicag.2010.06.020","article-title":"Crimean-Congo haemorrhagic fever in Eurasia","volume":"36","author":"Leblebicioglu","year":"2010","journal-title":"Int J of Antimicrobial Agents"},{"key":"10.1016\/j.vaccine.2017.05.031_b0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/QCO.0b013e3282a56a0a","article-title":"Crimean-Congo hemorrhagic fever","volume":"20","author":"Vorou","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0166-3542(04)00163-9","article-title":"Crimean-Congo hemorrhagic fever","volume":"64","author":"Whitehouse","year":"2004","journal-title":"Antiv Res"},{"key":"10.1016\/j.vaccine.2017.05.031_b0020","series-title":"Crimean hemorrhagic fever (acute infectious capillary toxicosis). Izdanie Otdel'noj Primorskoj Armii, Simferopol, USSR","article-title":"A new tick-borne virus disease-Crimean hemorrhagic fever (acute infectious capillary toxicosis)","author":"Chumakov","year":"1945"},{"key":"10.1016\/j.vaccine.2017.05.031_b0025","series-title":"Endemic viral infections: sborn trud inst polio virus encefal, akad med nauk USSR [Russian; NAMRU-3 translation T189]","first-page":"193","article-title":"A short review of the investigation of the virus of Crimean hemorrhagic fever","author":"Chumakov","year":"1965"},{"key":"10.1016\/j.vaccine.2017.05.031_b0030","first-page":"5","article-title":"On 30 years of investigation of Crimean hemorrhagic fever","volume":"22","author":"Chumakov","year":"1974","journal-title":"Trudi Inst Polio Virusn Entsefalitov Akad Med Nauk, USSR"},{"key":"10.1016\/j.vaccine.2017.05.031_b0035","first-page":"86","article-title":"Congo virus: a hitherto undescribed virus occurring in Africa. I. Human isolations\u2013clinical notes","volume":"44","author":"Simpson","year":"1967","journal-title":"East Afr Med J"},{"key":"10.1016\/j.vaccine.2017.05.031_b0040","series-title":"Crimean-congo hemorrhagic fever: a global perspective","first-page":"23","article-title":"Personal Reflections","author":"Woodall","year":"2007"},{"key":"10.1016\/j.vaccine.2017.05.031_b0045","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/jmedent\/44.6.1130","article-title":"Climate niches of tick species in the Mediterranean region: modeling of occurrence data, distributional constraints, and impact of climate change","volume":"44","author":"Estrada-Pena","year":"2007","journal-title":"J Med Entomol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0050","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrmicro2336","article-title":"The arrival, establishment and spread of exotic diseases: patterns and predictions","volume":"8","author":"Randolph","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","article-title":"Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity","volume":"100","author":"Bente","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.vaccine.2017.05.031_b0060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3201\/eid1605.091815","article-title":"Nosocomial outbreak of Crimean-Congo hemorrhagic fever, Sudan","volume":"16","author":"Aradaib","year":"2010","journal-title":"Emerg Inf Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coviro.2012.03.001","article-title":"Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries","volume":"2","author":"Ergonul","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0070","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4269\/ajtmh.2009.09-0051","article-title":"Crimean-Congo hemorrhagic fever virus as a nosocomial pathogen in Iran","volume":"81","author":"Mardani","year":"2009","journal-title":"The Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.05.031_b0075","doi-asserted-by":"crossref","first-page":"e1653","DOI":"10.1371\/journal.pntd.0001653","article-title":"Detection, isolation and confirmation of Crimean-Congo hemorrhagic fever virus in human, ticks and animals in Ahmadabad, India, 2010\u20132011","volume":"6","author":"Mourya","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jmv.23473","article-title":"Crimean-Congo hemorrhagic fever nosocomial infection in a immunosuppressed patient, Pakistan: case report and virological investigation","volume":"85","author":"Hasan","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0085","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.2005.72.471","article-title":"Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002: contact tracing and risk assessment","volume":"72","author":"Athar","year":"2005","journal-title":"The Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.05.031_b0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tmaid.2010.04.008","article-title":"Crimean-Congo hemorrhagic fever: risk for emergence of new endemic foci in Europe?","volume":"8","author":"Maltezou","year":"2010","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.trstmh.2005.03.002","article-title":"Crimean-Congo hemorrhagic fever: experience at a tertiary care hospital in Karachi, Pakistan","volume":"99","author":"Jamil","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.05.031_b0100","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ajic.2014.05.003","article-title":"Eid-ul-Azha festival in Pakistan: a vulnerable time for Crimean-Congo hemorrhagic fever outbreak","volume":"42","author":"Rehman","year":"2014","journal-title":"Am J Inf Control"},{"key":"10.1016\/j.vaccine.2017.05.031_b0105","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S1473-3099(16)30453-4","article-title":"Crimean-Congo haemorrhagic fever virus and Eid-Ul-Adha festival in Pakistan","volume":"16","author":"Mallhi","year":"2016","journal-title":"The Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0110","first-page":"9","article-title":"Consensus report: preventive measures for Crimean-Congo Hemorrhagic Fever during Eid-al-Adha festival","volume":"38","author":"Leblebicioglu","year":"2015","journal-title":"Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0115","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.antiviral.2013.02.007","article-title":"The impact of Crimean-Congo hemorrhagic fever virus on public health","volume":"98","author":"Mertens","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.vaccine.2017.05.031_b0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(02)00203-6","article-title":"Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control","volume":"57","author":"Sidwell","year":"2003","journal-title":"Antivir Res"},{"key":"10.1016\/j.vaccine.2017.05.031_b0125","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jama.1997.03550050080037","article-title":"Iraq's biological weapons. The past as future?","volume":"278","author":"Zilinskas","year":"1997","journal-title":"Jama."},{"key":"10.1016\/j.vaccine.2017.05.031_b0130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00000441-200206000-00004","article-title":"Viral agents as biological weapons and agents of bioterrorism","volume":"323","author":"Bronze","year":"2002","journal-title":"The Am J Medi Sci"},{"key":"10.1016\/j.vaccine.2017.05.031_b0135","first-page":"839","article-title":"Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis","volume":"121","author":"Burt","year":"1997","journal-title":"Arch Pathol Lab Med"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2017.05.031_b0140","doi-asserted-by":"crossref","first-page":"S794","DOI":"10.1093\/clinids\/11.Supplement_4.S794","article-title":"The clinical pathology of Crimean-Congo hemorrhagic fever","volume":"11","author":"Swanepoel","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0145","series-title":"Crimean-Congo hemorrhagic fever: a global perspective","first-page":"221","article-title":"Comparative Pathogenesis of Crimean Congo Hemorrhagic Fever and Ebola Hemorrhagic Fever","author":"Bray","year":"2007"},{"key":"10.1016\/j.vaccine.2017.05.031_b0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Ann Rev Pathol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0155","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1086\/500836","article-title":"Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever","volume":"193","author":"Ergonul","year":"2006","journal-title":"The J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0160","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1128\/CVI.00530-09","article-title":"Interacting roles of immune mechanisms and viral load in the pathogenesis of crimean-congo hemorrhagic fever","volume":"17","author":"Saksida","year":"2010","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.05.031_b0165","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jcv.2006.04.007","article-title":"Cytokine levels in Crimean-Congo hemorrhagic fever","volume":"36","author":"Papa","year":"2006","journal-title":"J Clin Virol: Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jmv.24312","article-title":"Cytokines as biomarkers of Crimean-Congo hemorrhagic fever","volume":"88","author":"Papa","year":"2016","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virol.2009.06.010","article-title":"Crimean Congo hemorrhagic fever virus infects human monocyte-derived dendritic cells","volume":"390","author":"Connolly-Andersen","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.05.031_b0180","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1099\/vir.0.015701-0","article-title":"Differential activation profiles of Crimean-Congo hemorrhagic fever virus- and Dugbe virus-infected antigen-presenting cells","volume":"91","author":"Peyrefitte","year":"2010","journal-title":"The J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0185","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1086\/521244","article-title":"Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever","volume":"45","author":"Cevik","year":"2007","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2017.05.031_b0190","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3201\/eid1311.070222","article-title":"Viral load as predictor of Crimean-Congo hemorrhagic fever outcome","volume":"13","author":"Duh","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0195","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3201\/eid1305.061588","article-title":"Viral load and Crimean-Congo hemorrhagic fever","volume":"13","author":"Papa","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0200","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1469-0691.2009.02996.x","article-title":"Emergence of Crimean-Congo haemorrhagic fever in Greece","volume":"16","author":"Papa","year":"2010","journal-title":"Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.diagmicrobio.2013.12.015","article-title":"Antibody responses and viral load in patients with Crimean-Congo hemorrhagic fever: a comprehensive analysis during the early stages of the infection","volume":"79","author":"Ergunay","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0210","first-page":"e449","article-title":"Crimean-Congo hemorrhagic fever disease due to tick bite with very long incubation periods","volume":"15","author":"Kaya","year":"2011","journal-title":"Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0215","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jmv.24141","article-title":"Crimean-Congo hemorrhagic fever: CXCL10 correlates with the viral load","volume":"87","author":"Papa","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0220","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jcv.2008.03.003","article-title":"Peripheral blood natural killer cells in Crimean-Congo hemorrhagic fever","volume":"42","author":"Yilmaz","year":"2008","journal-title":"J Clin Virol: Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0225","first-page":"560","article-title":"Analysis of lymphocyte subgroups in Crimean-Congo hemorrhagic fever","volume":"13","author":"Akinci","year":"2009","journal-title":"Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0230","doi-asserted-by":"crossref","first-page":"11089","DOI":"10.1128\/JVI.01383-10","article-title":"Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model","volume":"84","author":"Bente","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0235","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1099\/vir.0.019034-0","article-title":"Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice","volume":"91","author":"Bereczky","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0240","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.virusres.2006.03.005","article-title":"Exogenous nitric oxide inhibits Crimean Congo hemorrhagic fever virus","volume":"120","author":"Simon","year":"2006","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2017.05.031_b0245","first-page":"409","article-title":"Pathogenesis of experimental Crimean hemorrhagic fever infection in newborn white mice","volume":"17","author":"Smirnova","year":"1973","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0250","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0923-2516(96)81082-X","article-title":"Host-passage-induced phenotypic changes in crimean-congo haemorrhagic fever virus","volume":"146","author":"Gonzalez","year":"1995","journal-title":"Res Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0255","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/stem.170138","article-title":"Functional roles of STAT family proteins: lessons from knockout mice","volume":"17","author":"Akira","year":"1999","journal-title":"Stem Cells"},{"key":"10.1016\/j.vaccine.2017.05.031_b0260","unstructured":"Butenko AM, Chumakov MP, Smirnova SE, Vasilenko SM, Zavodova TI, Tkachenko EA, et al. Isolation of Crimean hemorrhagic fever virus from blood of patients and corpse material (from 1968\u20131969 investigation data) in Orstov, Astrakhan Oblast, and Bulgaria. Mater 3 Oblast Nauchn Prakt Konf (Rostov-on-Don, May 1970); 1970. p. 6\u201325. [Russian, translated NAMRU-3 T522]."},{"key":"10.1016\/j.vaccine.2017.05.031_b0265","first-page":"33","article-title":"Experimantal Congo virus (Ib-AN 7620) infection in primates","volume":"26","author":"Fagbami","year":"1975","journal-title":"Virologie"},{"key":"10.1016\/j.vaccine.2017.05.031_b0270","unstructured":"Garcia-Sastre A. Diversity, replication, pathogenicity and cell biology of Crimean Congo hemorrhagic fever virus. 2010."},{"key":"10.1016\/j.vaccine.2017.05.031_b0275","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcv.2008.09.013","article-title":"Successful treatment of severe Crimean-Congo hemorrhagic fever with supportive measures without ribavirin and hypothermia","volume":"44","author":"Yilmaz","year":"2009","journal-title":"J Clin Virol: Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0280","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4269\/ajtmh.1989.41.581","article-title":"Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin","volume":"41","author":"Watts","year":"1989","journal-title":"The Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.05.031_b0285","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1086\/375058","article-title":"The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran","volume":"36","author":"Mardani","year":"2003","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2017.05.031_b0290","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1741-7015-9-131","article-title":"Crimean-Congo hemorrhagic fever: epidemiological trends and controversies in treatment","volume":"9","author":"Maltezou","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2017.05.031_b0295","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcv.2009.11.007","article-title":"The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey","volume":"47","author":"Koksal","year":"2010","journal-title":"J Clin Virol: Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0300","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/00365548.2010.540036","article-title":"The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain","volume":"43","author":"Papa","year":"2011","journal-title":"Scandinavian J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0305","first-page":"7","article-title":"Vaccine against Congo-Crimean haemorhagic fever virus-Bulgarian input in fighting the disease","volume":"37","author":"Christova","year":"2010","journal-title":"Probl Infect Parasit Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0310","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/jmv.24400","article-title":"Molecular epidemiology of Crimean-Congo hemorrhagic fever in Bulgaria\u2013An update","volume":"88","author":"Papa","year":"2016","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0315","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2011.02.010","article-title":"Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies","volume":"90","author":"Keshtkar-Jahromi","year":"2011","journal-title":"Antivir Res"},{"key":"10.1016\/j.vaccine.2017.05.031_b0320","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1016\/j.vaccine.2012.08.003","article-title":"Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine","volume":"30","author":"Mousavi-Jazi","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.031_b0325","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM198702123160703","article-title":"Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination","volume":"316","author":"Hemachudha","year":"1987","journal-title":"The New England J Med"},{"key":"10.1016\/j.vaccine.2017.05.031_b0330","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.virusres.2003.12.035","article-title":"Crimean-Congo haemorrhagic fever virus: sequence analysis of the small RNA segments from a collection of viruses world wide","volume":"102","author":"Hewson","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2017.05.031_b0335","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1128\/JVI.01555-12","article-title":"Structure, function, and evolution of the Crimean-Congo hemorrhagic fever virus nucleocapsid protein","volume":"86","author":"Carter","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0340","series-title":"Fields virology","first-page":"1741","article-title":"Bunyaviridae","author":"Schmaljohn","year":"2007"},{"key":"10.1016\/j.vaccine.2017.05.031_b0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/14760584.8.1.67","article-title":"Recent approaches in hantavirus vaccine development","volume":"8","author":"Maes","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.05.031_b0350","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1016\/j.vaccine.2011.04.043","article-title":"A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-\/-) mice upon lethal virus challenge","volume":"29","author":"Boshra","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.031_b0355","first-page":"72","article-title":"Epitope-based immunoinformatics and molecular docking studies of nucleocapsid protein and ovarian tumor domain of crimean-congo hemorrhagic Fever virus","volume":"2","author":"Srinivasan","year":"2011","journal-title":"Fron Genet"},{"key":"10.1016\/j.vaccine.2017.05.031_b0360","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.1128\/JVI.76.14.7263-7275.2002","article-title":"Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus","volume":"76","author":"Sanchez","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0365","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.1128\/JVI.02730-06","article-title":"Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein","volume":"81","author":"Altamura","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0370","doi-asserted-by":"crossref","first-page":"8640","DOI":"10.1128\/JVI.77.16.8640-8649.2003","article-title":"Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1","volume":"77","author":"Vincent","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0375","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/JVI.80.1.514-525.2006","article-title":"Crimean-congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein","volume":"80","author":"Sanchez","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0380","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1743-422X-2-42","article-title":"Intracellular localization of Crimean-Congo Hemorrhagic Fever (CCHF) virus glycoproteins","volume":"2","author":"Haferkamp","year":"2005","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2017.05.031_b0385","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1128\/JVI.79.10.6152-6161.2005","article-title":"Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins","volume":"79","author":"Bertolotti-Ciarlet","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0390","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1099\/vir.0.81175-0","article-title":"Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus","volume":"86","author":"Ahmed","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0395","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1128\/CVI.05352-11","article-title":"Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus","volume":"18","author":"Ghiasi","year":"2011","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.05.031_b0400","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3181\/00379727-145-37933","article-title":"Neutralization and hemagglutination-inhibition tests with Crimean hemorrhagic fever-Congo virus","volume":"145","author":"Casals","year":"1974","journal-title":"Proc Soc Exp Biol Med Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2017.05.031_b0405","doi-asserted-by":"crossref","first-page":"e1004038","DOI":"10.1371\/journal.pcbi.1004038","article-title":"Potential benefits of cattle vaccination as a supplementary control for bovine tuberculosis","volume":"11","author":"Conlan","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0410","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/vim.2015.0127","article-title":"Avian influenza virus and DIVA strategies","volume":"29","author":"Hasan","year":"2016","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0415","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/tbed.12166","article-title":"A review of OIE country status recovery using vaccinate-to-live versus vaccinate-to-die foot-and-mouth disease response policies i: benefits of higher potency vaccines and associated NSP DIVA test systems in post-outbreak surveillance","volume":"62","author":"Barnett","year":"2015","journal-title":"Transbound Emerg Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0420","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jviromet.2011.11.020","article-title":"Development of an indirect ELISA method for the parallel measurement of IgG and IgM antibodies against Crimean-Congo haemorrhagic fever (CCHF) virus using recombinant nucleoprotein as antigen","volume":"179","author":"Dowall","year":"2012","journal-title":"J Virol Methods"},{"issue":"Pt 9","key":"10.1016\/j.vaccine.2017.05.031_b0425","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1099\/0022-1317-75-9-2157","article-title":"Detection of human antibodies to Crimean-Congo haemorrhagic fever virus using expressed viral nucleocapsid protein","volume":"75","author":"Marriott","year":"1994","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0430","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jmv.20270","article-title":"Recombinant nucleoprotein-based serological diagnosis of Crimean-Congo hemorrhagic fever virus infections","volume":"75","author":"Saijo","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0435","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/CDLI.6.1.55-60.1999","article-title":"Humoral response in Toscana virus acute neurologic disease investigated by viral-protein-specific immunoassays","volume":"6","author":"Magurano","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0440","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1096-9071(199606)49:2<83::AID-JMV2>3.0.CO;2-F","article-title":"Immunoblot detection of antibodies to Toscana virus","volume":"49","author":"Schwarz","year":"1996","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0445","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jmv.1890460402","article-title":"Human B-cell epitopes of Puumala virus nucleocapsid protein, the major antigen in early serological response","volume":"46","author":"Vapalahti","year":"1995","journal-title":"J Med Virol"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2017.05.031_b0450","doi-asserted-by":"crossref","first-page":"S801","DOI":"10.1093\/clinids\/11.Supplement_4.S801","article-title":"Antibody response in Crimean-Congo hemorrhagic fever","volume":"11","author":"Shepherd","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0455","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02076-16","article-title":"Immunization with DNA plasmids coding for crimean-congo hemorrhagic fever virus capsid and envelope proteins and\/or virus-like particles induces protection and survival in challenged mice","author":"Hinkula","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0460","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/vbz.2015.1855","article-title":"Crimean-Congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice","volume":"15","author":"Kortekaas","year":"2015","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0465","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jmv.20530","article-title":"Type I interferon inhibits Crimean-Congo hemorrhagic fever virus in human target cells","volume":"78","author":"Andersson","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0470","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1743-422X-9-122","article-title":"Expression of interferon-induced antiviral genes is delayed in a STAT1 knockout mouse model of Crimean-Congo hemorrhagic fever","volume":"9","author":"Bowick","year":"2012","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2017.05.031_b0475","first-page":"351","article-title":"Marker vaccines and the impact of their use on diagnosis and prophylactic measures","volume":"26","author":"Vannie","year":"2007","journal-title":"Revue Sci Tech"},{"key":"10.1016\/j.vaccine.2017.05.031_b0480","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/01652176.2001.9695094","article-title":"Present and future of veterinary viral vaccinology: a review","volume":"23","author":"van Oirschot","year":"2001","journal-title":"Veter Quart"},{"key":"10.1016\/j.vaccine.2017.05.031_b0485","doi-asserted-by":"crossref","first-page":"e0003579","DOI":"10.1371\/journal.pntd.0003579","article-title":"Immunization of knock-out alpha\/beta interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine","volume":"9","author":"Canakoglu","year":"2015","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0490","doi-asserted-by":"crossref","first-page":"e91516","DOI":"10.1371\/journal.pone.0091516","article-title":"A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model","volume":"9","author":"Buttigieg","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.05.031_b0495","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/21645515.2015.1078045","article-title":"A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease","volume":"12","author":"Dowall","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2017.05.031_b0500","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus","volume":"24","author":"Spik","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.031_b0505","series-title":"Rapid development of optimized recombinant adenoviral vaccines biosafety level 4 viruses: University of Manitoba","author":"Sahib","year":"2010"},{"key":"10.1016\/j.vaccine.2017.05.031_b0510","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1473-3099(06)70435-2","article-title":"Crimean-Congo haemorrhagic fever","volume":"6","author":"Ergonul","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0515","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3201\/eid1503.080687","article-title":"Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey","volume":"15","author":"Gunes","year":"2009","journal-title":"Emerging Infect Dis."},{"key":"10.1016\/j.vaccine.2017.05.031_b0520","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","article-title":"Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA","volume":"25","author":"Smith","year":"1983","journal-title":"Gene"},{"key":"10.1016\/j.vaccine.2017.05.031_b0525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-1-4899-1382-1_2","article-title":"Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates","volume":"397","author":"Moss","year":"1996","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0530","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","article-title":"Recombinant MVA vaccines: dispelling the myths","volume":"31","author":"Cottingham","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.031_b0535","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]","volume":"99","author":"Stickl","year":"1974","journal-title":"Deut Med Wochenschr"},{"key":"10.1016\/j.vaccine.2017.05.031_b0540","doi-asserted-by":"crossref","first-page":"19ra2","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass","volume":"2","author":"Alcock","year":"2010","journal-title":"Sci Translational Med"},{"key":"10.1016\/j.vaccine.2017.05.031_b0545","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0550","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.031_b0555","doi-asserted-by":"crossref","first-page":"e0156637","DOI":"10.1371\/journal.pone.0156637","article-title":"Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses","volume":"11","author":"Dowall","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.05.031_b0560","doi-asserted-by":"crossref","first-page":"11603","DOI":"10.1128\/JVI.75.23.11603-11613.2001","article-title":"Replication-defective vector based on a chimpanzee adenovirus","volume":"75","author":"Farina","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0565","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0570","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1586\/erv.13.15","article-title":"Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials","volume":"12","author":"Capone","year":"2013","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.05.031_b0575","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.vaccine.2009.03.080","article-title":"Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy","volume":"27","author":"Dudareva","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.031_b0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2010.07.043","article-title":"Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys","volume":"407","author":"Ersching","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.05.031_b0585","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.031_b0590","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0065-3527(06)68005-6","article-title":"Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce \u201cmammalianized\u201d recombinant glycoproteins","volume":"68","author":"Harrison","year":"2006","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2017.05.031_b0595","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1128\/JVI.03691-14","article-title":"A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus","volume":"89","author":"Devignot","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0600","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1099\/vir.0.80121-0","article-title":"Evidence of segment reassortment in Crimean-Congo haemorrhagic fever virus","volume":"85","author":"Hewson","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0605","first-page":"1","article-title":"Identification of highly conserved regions in L-segment of Crimean-Congo hemorrhagic fever virus and immunoinformatic prediction about potential novel vaccine","volume":"8","author":"Oany","year":"2015","journal-title":"Adv Appl Bioinfor Chem: AABC"},{"key":"10.1016\/j.vaccine.2017.05.031_b0610","first-page":"108","article-title":"Immunoinformatic analysis of crimean congo hemorrhagic fever virus glycoproteins and epitope prediction for synthetic peptide vaccine","volume":"26","author":"Tipu","year":"2016","journal-title":"J Coll Phys Surg\u2013Pakistan: JCPSP"},{"key":"10.1016\/j.vaccine.2017.05.031_b0615","doi-asserted-by":"crossref","first-page":"E838","DOI":"10.1073\/pnas.1218464110","article-title":"Deubiquitinase function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells","volume":"110","author":"van Kasteren","year":"2013","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.05.031_b0620","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/JVI.01859-09","article-title":"Crimean-Congo hemorrhagic fever virus-encoded ovarian tumor protease activity is dispensable for virus RNA polymerase function","volume":"84","author":"Bergeron","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0625","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/MED.0b013e328337282f","article-title":"Humanized mouse models to study human diseases","volume":"17","author":"Brehm","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.vaccine.2017.05.031_b0630","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0300985810372506","article-title":"Establishing efficacy of human products using animals: the US food and drug administration's \u201canimal rule\u201d","volume":"47","author":"Snoy","year":"2010","journal-title":"Veter Pathol"},{"key":"10.1016\/j.vaccine.2017.05.031_b0635","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jcv.2014.08.029","article-title":"Recent advances in research on Crimean-Congo hemorrhagic fever","volume":"64","author":"Papa","year":"2015","journal-title":"J Clin Virol: Off Publ Pan Am Soc Clin Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T14:59:31Z","timestamp":1602428371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17306552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":127,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17306552"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of vaccines against Crimean-Congo haemorrhagic fever virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}